Why PLM and eQMS should be one platform

The medical device industry has organized itself around two categories of software for the past two decades: Product Lifecycle Management for design data, and electronic Quality Management Systems for quality records. PLM holds your CAD files, BOMs, specifications, design inputs and outputs, and version history. The eQMS holds your CAPAs, NCRs, complaint records, audit findings, and document control. They are operated by different teams, built on different data models, and connected—in most organizations—by a combination of manual exports, shared drives, and institutional memory.

This separation made sense when these categories were invented. PLM emerged from manufacturing industries that needed to manage complex product data. eQMS emerged from quality management frameworks that needed to track compliance activities. Neither was built with the other in mind, and the medical device industry inherited both without rethinking the fundamental architecture.

The problem is that medical device development is not two separate activities. Design decisions and quality implications are the same activity viewed from different angles. When they live in separate systems, every connection between them must be maintained manually—and that maintenance cost compounds across every design iteration, every design change, and every audit.

What the separation actually costs

The most visible cost of PLM-eQMS separation is the documentation overhead it creates. When a design engineer changes a component specification, someone must determine which quality records reference that specification. Which risk controls depend on it? Which verification protocols tested it? Which supplier qualification is linked to it? Which CAPA was opened because of a nonconformance against it? In a separated system architecture, answering those questions requires manually cross-referencing across two systems that do not share a data model.

That cross-referencing is rarely done in real time. It happens when something forces it—a design review, an audit, a submission deadline. By the time the cross-referencing occurs, the gap between what changed in the PLM and what was updated in the eQMS may be weeks or months old. Reconciling that gap is the documentation work that most regulatory affairs teams describe as the most costly and error-prone part of their job.

The less visible cost is traceability degradation over the life of a program. In the first months of development, the connections between design decisions and quality records are fresh and clear. As the program matures, as team members turn over, as design iterations accumulate, as the gap between the two systems widens—the traceability that regulators require becomes increasingly dependent on tribal knowledge. The engineers who made the original decisions may no longer be on the team. The rationale for a specification that is now under CAPA scrutiny may exist only in an email thread from three years ago.

This is not a people problem. It is a systems architecture problem. The tools were not designed to maintain traceability across organizational boundaries and time horizons. Asking people to manually maintain that traceability at scale is asking them to do something that the architecture makes nearly impossible to do reliably.

The cascade problem in design changes

Design changes are where the PLM-eQMS separation creates its most acute regulatory exposure. Under 21 CFR 820.30(i), all design changes must be identified, documented, and where appropriate, reviewed and approved before implementation. The regulation further requires that the significance of the change be evaluated—does it require verification, validation, or both?

That evaluation requires understanding what the changed element touches. A dimensional change on a structural component may affect form, fit, and function—triggering verification testing. A material substitution may affect biocompatibility and sterilization validation. A firmware change may alter a safety-critical function, triggering IEC 62304 re-evaluation. The list of what a change touches determines the scope of what must be re-evaluated.

In a separated PLM-eQMS environment, that determination requires querying across two systems that do not share a common representation of the device. The PLM knows the component hierarchy. The eQMS knows which records reference components—but often by name string matching or manual cross-reference tables, not by a live link to the PLM data model. When a change is made and the PLM is updated, the eQMS does not know. Someone has to tell it, and that someone has to know to do so.

Missed cascade evaluations are among the most consequential design control failures from a regulatory perspective. An undocumented design change that was not evaluated for its impact on risk, verification, or validation is a 21 CFR 820.30 violation. More importantly, it is a patient safety issue—the whole point of requiring change evaluation is to catch situations where an apparently minor change has safety implications that are not immediately obvious.

The architectural argument for unification

When PLM and eQMS share a common data model on a single platform, the cascade problem becomes deterministic rather than dependent on human memory. A design change is not an event in one system that must be manually communicated to another—it is an event in a shared representation of the device that the platform understands in its full context. The platform knows which risk controls reference the changed element. It knows which verification protocols tested it. It knows which supplier qualifications depend on it. When the change is made, the platform surfaces the affected records automatically.

This is the architectural premise behind MANKAIND. The platform is not a PLM with quality modules bolted on, and it is not an eQMS with an engineering data import feature. It is a unified engineering intelligence platform built on the principle that design decisions and quality implications are the same information viewed from different perspectives—and that maintaining the connection between those perspectives is a platform responsibility, not a human one.

The practical consequence of that architecture is that design changes cascade through risk, traceability, and quality records automatically. Risk assessments reference live design data. Verification protocols link to the outputs they confirm. CAPAs connect to the design artifacts that generated them. When anything changes, the platform knows what to surface for review—because it understands the structure of the device and the structure of its regulatory record as a single, connected model.

What this means for regulatory strategy

The regulatory benefit of a unified platform is not just efficiency—it is defensibility. When an FDA inspector or notified body auditor asks to trace a design decision to its quality record, the answer in a unified platform is immediate and complete. The connection is not reconstructed from institutional memory—it was created at the moment the decision was made and has been maintained by the platform ever since.

For engineering teams preparing submissions, this changes the nature of pre-submission work. The question shifts from "do we have all the records we need?" to "are all the records the platform has maintained accurate and complete?" The first question requires a discovery effort. The second requires a review. Discovery takes months. Review takes weeks.

The separation of PLM and eQMS is an architectural choice that made sense for a different era. Medical device development today operates under tighter timelines, higher documentation requirements, and greater regulatory scrutiny than the systems were designed to handle. A platform that treats engineering decisions and quality management as a single integrated activity is not a marginal improvement—it is a different category of infrastructure entirely.